Thomas O'Neill on Muck Rack

Thomas O'Neill

Verified
Glasgow
As seen in: The Drum, The New York Times, Business Insider, Wiley Online Library, Science Magazine, Penn Live Patriot-News, The Lancet, InsideHook, EIN Presswire, LNP, Journal of the American Board of Family Medicine and
Creative
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Thomas

Contact Thomas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

OPINION: Should the Portsmouth Naval Shipyard be Portsmouth’s Naval Shipyard?

|
By Thomas O'Neill Verified
| granitegrok.com
On Friday, January 16, 2026, New Hampshire has a real opportunity to move a long-simmering border question out of the realm of vague historical dispute and into the realm of action. HR45—“urging Congress to find that the Piscataqua River and Portsmouth Harbor lie within the state of New Hampshire”—is scheduled for a public hearing at 1:30 p.m. in GP 228, followed by an executive session at 2:00 p.m. before the House Committee on State-Federal Relations and Veterans Affairs.
Open in Who Shared Issue with article?

Applications open for NHBC 2025 business graduate programme

|
By Thomas O'Neill Verified
| Connect East Midlands Verified
Following the success of its inaugural graduate scheme last year, NHBC will be opening applications for its 2025 business graduate programme for three weeks from Thursday 15 May 2025. As the UK’s largest provider of new home warranty and insurance, NHBC employs more than 1,300 talented and dedicated people. The fully funded two-year training and development programme, based at NHBC headquarters in Milton Keynes, will start in September 2025.
Open in Who Shared View Duplicates (2) Issue with article?

Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX‐622

|
By Michael Murphy, Celldex Therapeutics, Laura Vitale, Thomas O'Neill Verified
| Wiley Online Library Verified
1 Introduction Biologic-based therapies targeting cytokine pathways have resulted in marked clinical benefit in many inflammatory and autoimmune disorders [1]. However, many of these diseases are heterogeneous in nature and are generally driven by a multitude of cell types, pathways, or mechanisms, which inherently limits the effectiveness of most therapies directed at single targets.
Open in Who Shared Issue with article?
See all 22 licensed articles (46 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified